我們的團隊
管理團隊
Henry Lin, Ph.D.
創辦人暨執行長
Dr. Henry Lin為ANIVIA創辦人兼執行長，擁有創新醫療技術並為公司注入前瞻專業的企業家。完成全球首次且多例的人體臨床實驗，整合醫療團隊與技術團隊的優勢。林博士從信譽良好的投資機構募集資金，成就ANIVIA各階段里程碑。 林博士於哈佛大學主修免疫學，並於麻省綜合醫院與哈佛醫學院完成博士後研究。林博士於哈佛大學取得管理學院A.L.M.碩士學位，並獲得卓越學業成就獎。此外，他具有澳洲昆士蘭大學物理治療學士、生物科技碩士與醫學博士學位。
John Gilbert博士
技術長
John Gilbert博士是ANIVIA Medical的共同創始人及技術長，同時也是董事會成員。John Gilbert博士擁有超過50項已獲得的美國專利，並在創業執行長和技術長方面擁有豐富經驗，是醫療科技行業的專家，專注於創業運營、技術評估、法規、智慧財產權建立和商業模式開發。他在創造ANIVIA Medical的體外平臺技術及建立公司的智慧財產權組合方面發揮了關鍵作用。John Gilbert博士擁有哈佛大學的A.B.和M.A.學位，加州理工學院的物理學博士學位，並在麻省理工學院完成了博士後研究。
Leroy Yau
Chief of Staff
Leroy is an experienced executive and senior advisor with over 30 years in consulting, special situations, and venture building. A former Partner at EY in Hong Kong and Taiwan, he has led operational restructurings, cross-border mergers, and impact investments across global markets. His expertise spans corporate governance, enterprise risk management, and strategic innovation, guiding organizations through growth and transformation.
John Sasso
美洲區總經理
資深醫療科技領導者，擁有超過25年的工作經驗，包括在哈莫內蒂克斯（Haemonetics）、輻射醫療（Radi Medical，現為亞培 Abbott）和MITRE的角色。專長於運營、商業化和監管事務，並在策略和執行方面有著良好的業績紀錄。
Thomas Shannon
市場行銷主管
專長於全球行銷和商業發展，擁有超過30年的心血管和心肺領域經驗。曾在美敦力（Medtronic）、健德（Getinge）和弗瑞西斯醫療（Fresenius Medical Care）領導商業化、品牌策略和產品上市。曾任臨床灌注師，專長於體外生命支援（ECLS）、體外膜氧合（ECMO）和顛覆性醫療科技的商業化。
Julia Yuan
法規與臨床事務
法規和臨床專家，擁有超過25年的製藥和醫療科技行業經驗。在IQVIA、波士頓科學（Boston Scientific）和阿斯利康（AstraZeneca）領導臨床和法規策略。擁有豐富的臨床試驗、品質系統和全球法規途徑的專業知識，並專注於將創新醫療科技推向市場。
研究與開發
John Gilbert博士
技術長
John Gilbert博士是ANIVIA Medical的共同創始人及技術長，同時也是董事會成員。John Gilbert博士擁有超過50項已獲得的美國專利，並在創業執行長和技術長方面擁有豐富經驗，是醫療科技行業的專家，專注於創業運營、技術評估、法規、智慧財產權建立和商業模式開發。他在創造ANIVIA Medical的體外平臺技術及建立公司的智慧財產權組合方面發揮了關鍵作用。John Gilbert博士擁有哈佛大學的A.B.和M.A.學位，加州理工學院的物理學博士學位，並在麻省理工學院完成了博士後研究。
Lim Cheung,博士
工程資深副總裁
Lim Cheung博士擁有超過20年的醫療器械開發經驗，專注於放射學和微創手術。他監督了從概念、研發、工程、製造、品質、法規事務、臨床試驗到商業運營的每一個階段，無論是在大型跨國公司還是小型創業公司。作為Hologic和波士頓的Smith & Nephew的研發負責人、專利發明人和首席設計師，Lim Cheung博士帶領團隊開發的產品創造了數十億美元的累計收入和利潤。他擁有加州理工學院的電氣工程學士學位，以及馬裡蘭大學的物理學博士學位。他曾在NASA和哈佛大學擔任研究職位
John Sasso
美洲區總經理
John Sasso是一位技能嫻熟的專業人士，負責日常專案管理，包括產品開發、製造運營和質量活動，同時擔任管理代表和負責合規的負責人（PRRC）。他曾在Radi Medical Systems、Haemonetics、Neoventa Medical、Strohl Medical Technologies和Q-Urology等公司工作，擁有成功整合專案管理方法並將醫療器械商業化的良好記錄，涉及國內和外國的製造商。John Sasso在國際商務方面經驗豐富，曾將兩家外國醫療器械公司引入美國，其中一家年收入達到2800萬美元。John獲得了塔夫茨大學的電氣工程學士學位和碩士學位，以及本特利大學的工商管理碩士學位，以班級致辭人的身份畢業。
neuroAnivia Scientific Advisory Board
John Gilbert博士
Co-Founder and Chief Technology Officer, ANIVIA Medical
Dr. John Gilbert is a co-founder and Chief Technology Officer of ANIVIA Medical. He is a specialist in start-up operations, technology assessment, regulatory strategy, intellectual property creation, and business model development across the medical technology industry, with more than 50 issued U.S. patents and extensive experience as both a founding CEO and CTO. He played a pivotal role in inventing ANIVIA Medical’s extracorporeal platform technology and in establishing the company’s intellectual property portfolio. Dr. Gilbert holds an A.B. and M.A. from Harvard University, a Ph.D. in physics from the California Institute of Technology, and completed a postdoctoral fellowship at the Massachusetts Institute of Technology.
Jeffrey L. Saver, MD
Carol and James Collins Distinguished Professor of Neurology, David Geffen School of Medicine, UCLA
Director, UCLA Stroke Center
Dr. Jeffrey Saver is an internationally recognized leader in acute stroke treatment, stroke prevention, and clinical trial design. As founding Director of the UCLA Stroke Center, he co-led the development of mechanical thrombectomy from its early invention at UCLA through the pivotal 2015 breakthrough trials that established it as a global standard of care for ischemic stroke. He served as Principal Investigator of the NIH-NINDS FAST-MAG trial and as Global Co-Principal Investigator of the landmark SWIFT PRIME trial published in the New England Journal of Medicine. He has led more than 50 multicenter clinical trials and authored over 870 peer-reviewed publications. His honors include the American Heart Association’s Distinguished Scientist Award and the World Stroke Organization’s Lifetime Research Award. Dr. Saver earned his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his neurology residency in the Harvard-Longwood Program and fellowships in behavioral and cognitive neurology at the University of Iowa and in vascular neurology at Brown University.
Yih-Sharng Chen, MD, Ph.D.
Professor, Cardiovascular Surgery, National Taiwan University Hospital
Professor Yih-Sharng Chen is an internationally recognized cardiovascular surgeon and authority in extracorporeal membrane oxygenation (ECMO) and extracorporeal cardiopulmonary resuscitation (ECPR). He currently leads active heart transplantation and mechanical circulatory support programs at National Taiwan University Hospital, and his publications in ECPR have been a major influence on global practice in the ECMO field. He served as Chairman of the Asia-Pacific ELSO Chapter (APELSO) from 2017 to 2019 and as President of the Taiwan Society of Cardiovascular and Thoracic Surgery in 2017. He has authored more than 200 peer-reviewed papers and serves as a reviewer for leading journals in critical care, cardiothoracic surgery, and cardiology. Professor Chen earned his medical degree and Ph.D. from National Taiwan University, with additional post-residency training in Japan, the University of Michigan (USA), and Papworth Hospital (UK).
Kevin N. Sheth, MD
耶魯大學醫學院 神經學與神經外科教授
耶魯大學「腦與心智健康中心」創始主任
Dr. Kevin Sheth is an internationally recognized leader in acute neurological injury, stroke, and neurocritical care. His research focuses on cerebral edema, intracerebral hemorrhage, and secondary brain injury, with particular emphasis on therapies that limit neurologic damage following severe stroke. He has served as principal investigator on multiple NIH-funded multicenter clinical trials and has authored landmark studies on brain swelling and acute stroke management. His work has informed national stroke treatment guidelines, including analyses through the American Heart Association’s Get With The Guidelines–Stroke program and pivotal investigations of thrombolysis and thrombectomy outcomes. Dr. Sheth earned his A.B. from Johns Hopkins University and his M.D. from the University of Pennsylvania School of Medicine. He completed his internship at Brigham and Women’s Hospital, his neurology residency and chief residency in the Partners Neurology Program (Massachusetts General Hospital and Brigham & Women’s Hospital), and fellowships in critical care and vascular neurology at Harvard. His leadership in clinical trial design, neurocritical care innovation, and translational neuroscience continues to advance the field of stroke and brain injury management worldwide.
Reza Jahan, MD
Professor of Interventional Neuroradiology and Neurosurgery, David Geffen School of Medicine, UCLA
Member, UCLA Stroke Center
Dr. Reza Jahan is a leading expert in endovascular treatment of acute ischemic stroke, brain aneurysms, and cerebrovascular malformations. With more than 25 years of experience and over 1,500 cerebrovascular procedures performed, he has helped define modern interventional neuroradiology practice. He served as Senior Author on the landmark SWIFT PRIME trial published in the New England Journal of Medicine, which established mechanical thrombectomy as the standard of care for large vessel occlusion stroke. He has trained more than 30 physicians in interventional neuroradiology nationwide and has been recognized as a Super Doctors® Southern California honoree from 2023 to 2026. Dr. Jahan earned his B.S. in biochemistry from UCLA and his M.D. from the David Geffen School of Medicine at UCLA, where he was honored with the Leo G. Rigler Award and the Dean’s Scholar Award. He completed his medicine internship and radiology residency at UCLA, followed by subspecialty training in the UCLA Division of Interventional Neuroradiology.
Dayu Teng, Ph.D.
加州大學聖地牙哥分校 教授
加州大學聖地牙哥分校 醫學工程研究院 惠特克生物醫學工程中心（WCBE）共同主任
Dr. Dayu Teng is a translational researcher whose work bridges vascular biology, ischemic injury, and medical device safety. His research examines endothelial responses and vascular trauma during mechanical thrombectomy and other endovascular procedures, with the goal of improving procedural safety and clinical outcomes in stroke care. He has developed validated in vitro and large-animal platforms used to evaluate vascular response to intervention and has published widely on thrombectomy-related endothelial injury and therapeutic hypothermia. As Co-Director of the Whitaker Center for Biomedical Engineering at the UC San Diego Institute of Engineering in Medicine, Dr. Teng leads cross-disciplinary device research programs. He earned his Ph.D. from the University of California, San Diego. His research and technical leadership continue to shape the development of safer, next-generation neurovascular and critical care technologies.
如需更多信息， 請與我們聯繫.